Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | mRNA 5671 |
Synonyms | |
Therapy Description |
mRNA 5671 is a lipid nanoparticle encapsulated mRNA vaccine that targets KRAS G12D, G12V, G13D, and G12C, which potentially results in anti-tumor immune response (NCI Drug Dictionary). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
mRNA 5671 | mRNA-5671|V941|V 941 | mRNA 5671 is a lipid nanoparticle encapsulated mRNA vaccine that targets KRAS G12D, G12V, G13D, and G12C, which potentially results in anti-tumor immune response (NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03948763 | Phase I | mRNA 5671 mRNA 5671 + Pembrolizumab | A Study of mRNA-5671/V941 as Monotherapy and in Combination With Pembrolizumab (V941-001) | Completed | USA | NZL | AUS | 4 |